These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2572986)

  • 21. Drug pumps for treatment of neurologic diseases and pain.
    Penn RD
    Neurol Clin; 1985 May; 3(2):439-51. PubMed ID: 2862572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview.
    Jakki SL; Senthil V; Yasam VR; Chandrasekar MJN; Vijayaraghavan C
    Curr Drug Targets; 2018; 19(2):155-169. PubMed ID: 28606049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of parkinsonism by intraventricular bethanechol in a patient with Alzheimer's disease.
    Fox JH; Bennett DA; Goetz CG; Penn RD; Savoy S; Clasen R; Wilson RS
    Neurology; 1989 Sep; 39(9):1265. PubMed ID: 2570380
    [No Abstract]   [Full Text] [Related]  

  • 24. Intracerebroventricular cholinergic drug administration in Alzheimer's disease: preliminary results of a double-blind study.
    Harbaugh RE
    J Neural Transm Suppl; 1987; 24():271-7. PubMed ID: 2890709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracerebral drug delivery in rats with lesion-induced memory deficits.
    Howard MA; Gross A; Grady MS; Langer RS; Mathiowitz E; Winn HR; Mayberg MR
    J Neurosurg; 1989 Jul; 71(1):105-12. PubMed ID: 2567778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alzheimer's Disease Targeted Nano-Based Drug Delivery Systems.
    Altinoglu G; Adali T
    Curr Drug Targets; 2020; 21(7):628-646. PubMed ID: 31744447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Nanoparticles for the Treatment of Alzheimer's Disease.
    Martín-Rapun R; De Matteis L; Ambrosone A; Garcia-Embid S; Gutierrez L; de la Fuente JM
    Curr Pharm Des; 2017; 23(13):1927-1952. PubMed ID: 28025949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.
    Roney C; Kulkarni P; Arora V; Antich P; Bonte F; Wu A; Mallikarjuana NN; Manohar S; Liang HF; Kulkarni AR; Sung HW; Sairam M; Aminabhavi TM
    J Control Release; 2005 Nov; 108(2-3):193-214. PubMed ID: 16246446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier.
    Wong KH; Riaz MK; Xie Y; Zhang X; Liu Q; Chen H; Bian Z; Chen X; Lu A; Yang Z
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted drug delivery across the blood brain barrier in Alzheimer's disease.
    Rocha S
    Curr Pharm Des; 2013; 19(37):6635-46. PubMed ID: 23621533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease.
    Batool A; Kamal MA; Rizvi SMD; Rashid S
    Curr Drug Metab; 2018; 19(8):704-713. PubMed ID: 29512457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell delivery to the central nervous system.
    Shoichet MS; Winn SR
    Adv Drug Deliv Rev; 2000 Aug; 42(1-2):81-102. PubMed ID: 10942816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group.
    DeKosky ST; Harbaugh RE; Schmitt FA; Bakay RA; Chui HC; Knopman DS; Reeder TM; Shetter AG; Senter HJ; Markesbery WR
    Ann Neurol; 1992 Nov; 32(5):625-32. PubMed ID: 1360195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of the blood-CNS barrier in CNS disorders and their treatment.
    Palmer AM
    Neurobiol Dis; 2010 Jan; 37(1):3-12. PubMed ID: 19664711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
    Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
    J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
    Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
    Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applications of nanotechnology in drug delivery to the central nervous system.
    Saeedi M; Eslamifar M; Khezri K; Dizaj SM
    Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease.
    Fonseca-Santos B; Gremião MP; Chorilli M
    Int J Nanomedicine; 2015; 10():4981-5003. PubMed ID: 26345528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New directions in CNS drug delivery.
    Langer R; Brem H; Langer LF
    Neurobiol Aging; 1989; 10(5):642-4; discussion 648-50. PubMed ID: 2812246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." Alzheimer's disease drugs: more than one barrier to breach.
    Roher AE; Kokjohn TA
    Alzheimers Dement; 2009 Sep; 5(5):437-8. PubMed ID: 19751925
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.